Skip to main content
ALMS logo

ALMS · Alumis Inc.

Track ALMS — free
$22.38 -0.83 (-3.58%) At close · Aug 28
Market Cap
$2.90B
Shares
129.44M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$24.05M
FY2025
Net Income
-$243.33M +17.3%
FY2025 Net Income FY2023–FY2025
Operating Margin
-1886.92%
FY2025
Diluted EPS
-$2.86 +72.4%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
-$369.52M -44.9%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023
$7.4M $24.05M
$347.5M $386M $265.55M $137.68M
$77.08M $91.86M $35.2M $20.5M
$3.42M $3.5M $3.15M $1.28M
$466.4M $477.85M $300.75M $158.17M
-$459M -$453.8M -$300.75M -$158.17M
-1886.92%
-$455.58M -$450.31M -$297.6M -$156.89M
$18.29M $201.92M $6.52M $3.18M
-$251.89M -$294.23M
-$8.56M $0 $0
-$438.96M -$243.33M -$294.23M -$154.99M
-1011.75%
-$439.66M -$243.18M -$294.2M -$154.86M
USD/shares -$3.67 -$2.86 -$10.38 -$72.08
USD/shares -$3.66 -$2.86 -$10.38 -$72.08
shares 85.03M 28.34M 2.15M
shares 85.03M 28.34M 2.15M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $87K in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Peer median 7.22×
EV/EBIT
Peer median 16.58×
P/E (TTM)
Peer median 17.50×

Peer medians compare against the 231 similar-size Biotechnology companies (of 524 listed).

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025
Single Reportable Segment $24,050,000

By Product & Service (USD)

Component FY2025
License $17,389,000
Collaboration Revenue $6,661,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023
Single Reportable Segment -$453,804,000 -$300,754,000 -$158,174,000

Operating Margin by Segment (%)

Component FY2025
Single Reportable Segment -1886.9%
Key facts CIK 1847367 CUSIP 022307102 13F (30d) 177 filings 175 filers Visit website Investor relations